The DOI matches its Crossref record.
Impurities in New Drug Products
Abstract
I. INTRODUCTION A. Objective of the Guideline This guideline is intended to assist to the extent possible, in the establishment of a single set of global specifications for new drug substances and new drug products. It provides guidance on the setting and justification of acceptance criteria and the selection of test procedures for new drug substances of synthetic chemical origin, and new drug products produced from them, which have not been registered previously in the United States, the European Union, or Japan.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Development of forced degradation and stability indicating studies of drugs—A review
Blessy, M., Patel, R. D., Prajapati, P. N., & Agrawal, Y. K. (2014) · Journal of Pharmaceutical Analysis · doi:10.1016/j.jpha.2013.09.003 · Cited by 1,032
Analytical techniques in pharmaceutical analysis: A review
Siddiqui, M. R., AlOthman, Z. A., & Rahman, N. (2017) · Arabian Journal of Chemistry · doi:10.1016/j.arabjc.2013.04.016 · Cited by 798
Q2(R1) Validation of Analytical Procedures: Text and Methodology
Borman, P., & Elder, D. (2017) · ICH Quality Guidelines · doi:10.1002/9781118971147.ch5 · Cited by 746
The market of chiral drugs: Chiral switches versus de novo enantiomerically pure compounds
Calcaterra, A., & D’Acquarica, I. (2018) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/j.jpba.2017.07.008 · Cited by 481
Q8(R2): Pharmaceutical Development
Holm, P., Allesø, M., Bryder, M. C., & Holm, R. (2017) · ICH Quality Guidelines · doi:10.1002/9781118971147.ch20 · Cited by 142
Metadata
- Venue
- Handbook of Pharmaceutical Manufacturing Formulations
- Publisher
- CRC Press
- Published
- 2009-09-21
- Pages
- 123-129
- OpenAlex
- W2499861207
- Cited by
- 205
- References
- 0
- FWCI
- 17.16
- Type
- book chapter
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Impurities in New Drug Products. https://app.cochat.ai/papers/10.3109/9781420081275-18
- The paper
- Impurities in New Drug Products. (2009). Handbook of Pharmaceutical Manufacturing Formulations. https://doi.org/10.3109/9781420081275-18
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.